Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

Sickle-cell disease

Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia

Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340

Fetal hemoglobin in sickle cell anemia

Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553

GBT 440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

Oksenberg, D., Dufu, K., Patel, M. P., Chuang, C.-Y., Li, Z., Xu, Q. R., Silva‐Garcia, A., Zhou, C., Hutchaleelaha, A., Patskovska, L. N., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14214 · Cited by 244

Residue-Specific pKa Determination of Lysine and Arginine Side Chains by Indirect 15N and 13C NMR Spectroscopy: Application to apo Calmodulin

André, I., Linse, S. S., & Mulder, F. A. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0721824 · Cited by 119

Determination of the pK values for the alpha-amino groups of human hemoglobin.

Garner, M. H., Bogardt, R. A., & Gurd, F. R. N. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41315-x · Cited by 107

Structural Basis for the Potent Antisickling Effect of a Novel Class of Five-Membered Heterocyclic Aldehydic Compounds

Safo, M. K., Abdulmalik, O. Y., Danso-Danquah, R. E., Burnett, J. C., Nokuri, S., Joshi, G. S., Musayev, F. N., Asakura, T., & Abraham, D. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0498001 · Cited by 96

Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin

Abdulmalik, O. Y., Ghatge, M. S., Musayev, F. N., Parikh, A., Chen, Q., Yang, J., Nnamani, I., Danso-Danquah, R. E., Eseonu, D. N., Asakura, T., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911036353 · Cited by 52

Pyridyl Derivatives of Benzaldehyde as Potential Antisickling Agents

Nnamani, I., Joshi, G. S., Danso-Danquah, R. E., Abdulmalik, O. Y., Asakura, T., Abraham, D. J., & Safo, M. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890165 · Cited by 45

EFFECT OF BW12C ON OXYGEN AFFINITY OF HAEMOGLOBIN IN SICKLE-CELL DISEASE

Keidan, A. J., White, R. D., Huehns, E. R., FRANKLIN, I. M., Joy, M., & Stuart, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90941-4 · Cited by 42

Therapeutic Strategies for the Treatment of Sickle Cell Disease

Safo, M. K., Aljahdali, A. S., Burnett, J. C., Abraham, D. J., & Abdulmalik, O. Y. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc270 · Cited by 9

Modulation of the allosteric and vasoregulatory arms of erythrocytic oxygen transport

Wise, T. J., Ott, M. E., Joseph, M. S., Welsby, I. J., Darrow, C. C., & McMahon, T. J. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1394650 · Cited by 10

Research progress on covalent inhibitors targeting alkaline amino acids

Zhao, B., Xu, S., Zhou, S., Jiang, X., Jiang, A., Lei, H., & Zhai, X. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108800 · Cited by 8

Structure-based rational design of covalent probes

Holcomb, M., Llanos, M. A., Hansel-Harris, A., & Forli, S. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01606-y · Cited by 9

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint

Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n-v2 · Cited by 8

Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review

Patel, Z. V., Prajjwal, P., Bethineedi, L. D., Patel, D., Khullar, K., Patel, H., Khatri, K., Marsool, M. D. M., Gadam, S., Aleti, S., et al. (2024) · Journal of Blood Medicine · doi:10.2147/jbm.s477507 · Cited by 12

Hemoglobinopathies—genetically diverse, clinically complex, and globally relevant

Cario, H. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0402-4 · Cited by 7

Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease

Vunnam, N., Hansen, S., Williams, D. C., Been, M., Lo, C. H., Pandey, A. K., Paulson, C. N., Rohde, J. A., Thomas, D. D., Sachs, J. N., et al. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00671 · Cited by 7

Blocking HbS Polymerization in SCD

Lettre, G. (2020) · Cell · doi:10.1016/j.cell.2020.01.019 · Cited by 6

How I approach disease‐modifying therapy in children with sickle cell disease in an era of novel therapies

Karkoska, K. A., & McGann, P. T. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29363 · Cited by 6

Rheological Impact of GBT1118 Cessation in a Sickle Mouse Model

Kanne, C. K., Nébor, D., Pochron, M. P., Oksenberg, D., & Sheehan, V. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.742784 · Cited by 6

Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease

Huang, B., Ghatge, M. S., Donkor, A. K., Musayev, F. N., Deshpande, T. M., AlAwadh, M. A., Alhashimi, R. T., Zhu, H., Omar, A. M., Telen, M. J., et al. (2022) · Molecules · doi:10.3390/molecules27206835 · Cited by 8

Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies

Lobitz, S., Élion, J., Colombatti, R., & Cela, E. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-615-4 · Cited by 6

Computational molecular biology

Pal, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814855-6.00018-3 · Cited by 6

Lysine targeting covalent inhibitors of malarial kinase Pf CLK3

Brettell, S. B., Cann, G., Begen, A., Sharma, S., Mahindra, A., Carruthers, L. V., Milligan, G., Clarke, D. J., Tobin, A. B., & Jamieson, A. G. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00335k · Cited by 5

It's ok to be outnumbered – sub-stoichiometric modulation of homomeric protein complexes

Dimitrova, Y. N., Gutierrez, J. A., & Huard, K. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00212d · Cited by 6

Osivelotor for the treatment of sickle cell disease

Cannas, G. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2489123 · Cited by 5

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

Lisbon, E. A., Brown, C., Redfern, A., Duchin, K., Barth, A., Roberts, E. S., Gaputan, P., Dufu, K., Lo, A., Pochron, M. P., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70028 · Cited by 6

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease

Barriteau, C. M., & Badawy, S. M. (2022) · Journal of Blood Medicine · doi:10.2147/jbm.s362222 · Cited by 5

Novel Strategy To Inhibit Transthyretin Amyloidosis via the Synergetic Effect of Chemoselective Acylation and Noncovalent Inhibitor Release

Lee, S. B., Yu, J., Kim, H., Kim, K. W., Jeong, J. W., Kim, Y. L., Park, S. J., Koo, T., Lee, C., Hong, K. B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01926 · Cited by 5

Targeting HbS Polymerization

Ferrone, F. A. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.012 · Cited by 5

Voxelotor for the Treatment of Sickle Cell Disease

Fantasia, H. C., & Morse, B. L. (2020) · Nursing for Women s Health · doi:10.1016/j.nwh.2020.03.003 · Cited by 4

Targeted modification of furan‐2‐carboxaldehydes into Michael acceptor analogs yielded long‐acting hemoglobin modulators with dual antisickling activities

Omar, A. M., Abdulmalik, O. Y., El‐Say, K. M., Ghatge, M. S., Cyril-Olutayo, M. C., Paredes, S. D., AlAwadh, M. A., El‐Araby, M. E., & Safo, M. K. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14371 · Cited by 5

Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease

Ahmed, T. A., El‐Say, K. M., Abd-Allah, F. I., Omar, A. M., El‐Araby, M. E., Muhammad, Y. A., Pagare, P. P., Zhang, Y., Mohmmad, K. A., Abdulmalik, O. Y., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081148 · Cited by 5

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma

Savić, R. M., GREEN, M. L., Jorga, K. M., Zager, M. A., & Washington, C. B. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12731 · Cited by 4

Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization Inhibitor

Li, Z., Alt, C., Dufu, K., Hutchaleelaha, A., Xu, Q. R., Zhang, X., Li, C.-M., Rademacher, P., Bosmajian, C., Pochron, M. P., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00076 · Cited by 4

Tumor microenvironment-responsive self-assembled nanomedicine for reversible covalent targeting of BCR-ABL kinase

Xiang, M., Yang, F., Chen, P., Chen, J., Zhang, J., Yang, J., Liu, Y., Zhang, Q., Pi, J., Yuan, P., et al. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111423 · Cited by 4

Time-dependent interaction of benzohydrazide with trifluoroacetyl-2-furanoylmethane: Hydrazone versus pyrazoline formation

Panova, E. V., Tursunov, M. A., Ruzieva, M. J., Voronina, J. К., & Safin, D. A. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145834 · Cited by 4

Cytochrome P450 in GtoPdb v.2023.1

Burns, K. E., & Helsby, N. A. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f242/2023.1 · Cited by 4

Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde

Alhashimi, R. T., Ahmed, T. A., Alghanem, L., Pagare, P. P., Huang, B., Ghatge, M. S., Omar, A. M., Abdulmalik, O. Y., Zhang, Y., & Safo, M. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112547 · Cited by 4

Concise approach for the synthesis of Voxelotor for sickle cell disease

Manda, J., & Reddy, B. V. S. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133768 · Cited by 4

Targeted therapeutic management based on phytoconstituents for sickle cell anemia focusing on molecular mechanisms: Current trends and future perspectives

Islam, M. R., Rauf, A., Akash, S., Sharker, M., Mahreen, M., Munira, M. A. K., Dhar, P. S., Hemeg, H. A., Iriti, M., & Imran, M. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155936 · Cited by 4

X-ray crystallography and sickle cell disease drug discovery—a tribute to Donald Abraham

Donkor, A. K., Pagare, P. P., Mughram, M. H. A., & Safo, M. K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1136970 · Cited by 4

Sticking together: Polymerization of sickle hemoglobin drives the multiscale pathophysiology of sickle cell disease

Williams, D. C., Szafraniec, H. M., & Wood, D. K. (2025) · Biophysics Reviews · doi:10.1063/5.0238698 · Cited by 4

Sustainable production of chemicals by algorithm-assisted (bio)synthesis

Grzybowski, B. A., Żądło‐Dobrowolska, A., Onishchenko, N. R., & Larsen, E. S. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00312-7 · Cited by 7

A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2

Hillebrand, L., Wang, G., Rasch, A., Masberg, B., Chaikuad, A., Kronenberger, T., Günther, E., Förster, M., Poso, A., Lämmerhofer, M., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00440c · Cited by 3

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

Basu, R., & Fletcher, S. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70377 · Cited by 3

Quantitative assessment of the in-vitro binding kinetics of antisickling aromatic aldehydes with hemoglobin A: A universal HPLC-UV/Vis method to quantitate Schiff-base adduct formation

Xu, X., Ghatge, M. S., Huang, B., Alghamdi, A., Wang, H., Pierce, B. D., Abdulmalik, O. Y., Zhang, Y., Safo, M. K., & Venitz, J. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115152 · Cited by 3

Effect of Hb conformational changes on oxygen transport physiology.

Yin, Z., Li, D., Guo, Q., Wang, R., & Li, W. (2024) · PubMed Central · doi:10.11817/j.issn.1672-7347.2024.230199 · Cited by 3

Current and emerging drug treatment strategies to tackle sickle cell anemia

Persaud, Y., Leonard, A. K., & Rai, P. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2379260 · Cited by 3

Structure based design, synthesis and identification of novel covalent reversible dual TLR2/TLR9 small molecule antagonists

Natala, S. R., Habas, A., Stocking, E. M., Orry, A. J. W., Abagyan, R. A., Makale, M., & Wrasidlo, W. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130259 · Cited by 3

Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia

Abdulmalik, O. Y., Darwish, N. H. E., Muralidharan-Chari, V., Taleb, M. A., & Mousa, S. A. (2021) · Haematologica · doi:10.3324/haematol.2020.272393 · Cited by 3

Functionalized 2‐Hydroxybenzaldehyde‐PEG Modules as Portable Tags for the Engagement of Protein Lysine ϵ‐Amino Groups

Sacco, G., Stammwitz, S., Belvisi, L., Pignataro, L., Corso, A. D., & Gennari, C. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100160 · Cited by 3

Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin

Enakaya, N. A., Jefferson, A., Chew-Martinez, D., & Matthews, J. S. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00590 · Cited by 3

Doping control approach: Identification of equine in vitro metabolites of voxelotor (GBT440), a hemoglobin S polymerization inhibitor

Subhahar, M. B., Kal, A. K. K., Philip, M., Ajeebsanu, M. M., Karatt, T. K., & Perwad, Z. (2023) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9671 · Cited by 3

Advances in pharmacotherapy for sickle cell disease: what is the current state of play?

Alan, S., & Kanter, J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2377711 · Cited by 3

Why medicines work

Swinney, D. C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108175 · Cited by 3

Go for Gold: Development of a Scalable Synthesis of [1‐(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors

Rebhan, L., Fürst, R., Schollmeyer, D., Serafim, R. A. M., & Gehringer, M. (2025) · ChemistryOpen · doi:10.1002/open.202500106 · Cited by 2

Cocrystals of the Highly Potent Sickle Cell Anemia Drug Voxelotor with Trimesic Acid: A Substantial Enhancement in In Vitro Dissolution Performance at Physiological pH

Khan, A. A., Shaikh, T. R., George, C. P., & Gonnade, R. G. (2025) · Crystal Growth & Design · doi:10.1021/acs.cgd.5c00300 · Cited by 2

Oxygen dissociation curve inflection point during incremental exercise: a trigger for the Bohr effect

Burchert, H. H., Stringer, W. W., & Dash, R. K. (2025) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-025-03100-9 · Cited by 2

Synthesis and structural elucidation of a trifluoromethylated cyclopentene hydrazone: a combined X-ray and computational study

Panova, E. V., Ganiev, B. S., Гиясович, А. К., Umarov, B. B., Voronina, J. К., & Safin, D. A. (2026) · New Journal of Chemistry · doi:10.1039/d6nj00632a · Cited by 2

Photochemical Deracemization of Aza-1-isoindolinones: Critical Influence of Catalyst Substitution and the Nature of Its Resting State

Freund, P., Pauls, M., Jänchen, M., Zuber, J., Hauer, J., Bannwarth, C., & Bach, T. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c05440 · Cited by 2

Paradigm Shift for Designing Oxygen Therapeutics: New Insights Emerging from Studies with Transgenic Mouse Models of Sickle Cell Disease

Acharya, S. A., Branch, C. A., Tsai, A. G., & Intaglietta, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-95975-3_20 · Cited by 2

Modeling the public health impact of voxelotor in the management of sickle cell disease in France

Galactéros, F., Ethgen, O., & Beillat, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291211 · Cited by 2

A quantum chemistry background of sickle cell anemia and gaps in antisickling drug development

Suhail, M., Usmani, S., & Ahmad, M. (2023) · European Journal of Chemistry · doi:10.5155/eurjchem.14.3.370-375.2455 · Cited by 2

The Role of Non-genetic Therapies to Reduce the Incidence of Sickle Cell Crisis: A Systematic Review

Pingili, S., Makkena, V. K., Jaramillo, A. P., Awosusi, B. L., Ayyub, J., Dabhi, K. N., Gohil, N. V., Tanveer, N., Hussein, S., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.42785 · Cited by 2

Case studies in rare disease small molecule discovery and development

Schmidt, D. R., & Thompson, C. V. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127462 · Cited by 2

A primer on harnessing non-enzymatic post-translational modifications for drug design

Long, M. J. C., Ly, P., & Aye, Y. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00157d · Cited by 1

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint

Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Ralhan, K., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n · Cited by 2

Challenges of the allosteric regulation of hemoglobin by interaction with Cys93 of the β chain for the treatment of sickle cell disease

Niesor, E. J., Perez, A., Bordat, C., Laghrissi‐Thode, F., Nader, É., & Connes, P. (2025) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoaf012 · Cited by 1

Clinically approved small-molecule drugs for anemia therapy

Wang, Y., Zhao, W., Yao, S., Ni, S., Feng, C., & Wang, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117623 · Cited by 1

Drug discovery technologies–Current and future trends

Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1

Potent Antisickling Furaldehyde Analogs for Acute Sickle Cell Therapy: Enhanced Efficacy and Intravenous Formulation Potential

Omar, A. M., El‐Araby, M. E., Ahmed, T. A., Donkor, A. K., Opare, A., Ghatge, M. S., Aljahdali, A. S., Alhashimi, R. T., Robinson, T., Balogun, B., et al. (2025) · ChemMedChem · doi:10.1002/cmdc.202500507 · Cited by 1

Synthesis, optical properties and in silico studies of the Schiff base with bulky aromatic fragments

Panova, E. V., Voronina, J. К., Azizova, A. N., Tutar, Ö. F., Mahmoudi, G., & Safin, D. A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144637 · Cited by 1

Targeting enzymes with covalent warheads: Beyond cysteine

Patel, D., Sharma, A., & Duncan, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00064-9 · Cited by 1

Expanding the landscape of covalent drug discovery: irreversible targeting of non‐cysteine residues

Srinivasan, B., & Taylor, J. B. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70604 · Cited by 2

Characterization of the Second-Generation Covalent Fragment Library (CovLib Gen2): Thiol Reactivity Profiling and p53-Y220C Rescue

Schwer, M., Aldea, S., Engelhardt, M., Stahlecker, J., Rheinganz, J., Langkamp, A., & Boeckler, F. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s598622 · Cited by 1

Voxelotor: novel drug for sickle cell disease

Singh, J., Maggo, S., & Sadananden, U. K. (2020) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20200732 · Cited by 1

Target Validation—Prosecuting the Target

Jones, L. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00014-1 · Cited by 1

More to voxelotor than meets the eye?

Bovino, R. C., Jackson, A. C., & Ferrone, F. A. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007702 · Cited by 1

Voxelotor (GBT440) in pediatric sickle cell disease: A review

Jamalapur, S. L., Glaros, A. K., & Ravindranath, Y. (2024) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2024.07.006 · Cited by 1

Preclinical therapeutics for sickle cell disease: modern developments and future considerations

Okpala, I. E., Nonyelu, C. E., Muoghalu, E., Anigbogu, I. O., Onodugo, C., Ilechukwu, G. U., Fidelis-Ewa, U., Duru, A. N., & Okoye, H. C. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2500289 · Cited by 1

Michael Acceptor Compounds as Hemoglobin Oxygen Affinity Modulators for Reversing Sickling of Red Blood Cells

Mohammad, K. A., Naghi, A. H., Ghatge, M. S., Balogun, B., Macias, M., Roland, S., Opare, A., Abdulmalik, O. Y., Safo, M. K., Omar, A. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060783 · Cited by 1

Cancer and Beyond: Discovery and Development of NO-Releasing Therapeutics

Scicinski, J. J., & Kashfi, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816545-4.00007-4 · Cited by 1

100 years of sickle cell disease research: etiology, pathophysiology and rational drug design (part 1)

Mahran, M. A., Teleb, M., & Abdelkader, E. H. (2019) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-019-0016-x · Cited by 1

A practical synthesis of voxelotor

Kang, L., Mao, Y., Jiang, S., & Lu, S. (2022) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4535 · Cited by 1

Voxelotor (Oxbryta) Binds Multiple Hemoglobin Sites and Influences Protein StructurePreprint

Tamanaha, M. D. L. C., Cabrera, E. F., Sargeant, J., Gershon, P. D., Samuel, P. P., & Cocco, M. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.653546 · Cited by 1

A “Split” Hemoglobin S Peak

Colby, J. M., & Shajani-Yi, Z. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa135

Voxelotor: Changing the Disease by Changing the Conformation

Osunkwo, I., Wilsonn, S., Little, J. A., & Monahan, K. (2019) · The Hematologist · doi:10.1182/hem.v16.6.9968

Beyond Inhibition

Kostić, M., & Jones, L. H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch15

Rh-Catalyzed C–H Functionalization of the (Pyrazol-5-yl)pyridine Core of GBT-440

Ramana, C. V., Kalshetti, R. G., & Halnor, S. V. (2023) · Synthesis · doi:10.1055/a-2116-6734

Chemistry of Covalent Drugs: Chemical Reactions with Endogenous Proteins in Live Cells

Shindo, N., & Ojida, A. (2024) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.82.50

Orthopedic Complications Of Sickle Cell Disease: A Retrospective Evaluation Of 469 Patients In Port Harcourt, Nigeria

Aaron, F. E., Dublin-Green, L. A., Ijah, R. F. O. A., Maduka, A. D., & EOmunakwe, H. (2024) · Advances In Clinical And Medical Research · doi:10.52793/acmr.2024.5(1)-69

Systematic Development of a Gradient Elution HPLC Method for the Analysis of Voxelotor and Its Structurally Related Substances Applying Analytical Quality by Design Approach

Bommi, S., Jayanty, S., Kola, S., & Kallam, V. S. R. K. R. (2024) · Chromatographia · doi:10.1007/s10337-024-04378-0

Recent highlights in covalent inhibitor design

Marino, K. A., Nicewonger, R., Zhang, H., & Thorarensen, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00010-8

Sickle Cell Anemia

Platt, M. O., Lee, H. S., & Hatoum, L. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_11 · Cited by 1

Quantitative Engineering Approaches to Understand the Multiscale Biophysical, Biomechanical, and Rheological Pathophysiology of Sickle Cell Disease

Szafraniec, H. M., Williams, D. C., & Wood, D. K. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_1

Hemoglobin: A Target for Sickle Cell Disease Drug Discovery

Donkor, A. K., Opare, A., Thomas, W., Abdulmalik, O. Y., Zhang, Y., & Safo, M. K. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_10

Exploring the latest emerging drugs for the treatment of sickle cell disease

Cannas, G. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2650178

Measurement and analysis of the protective effects of anti-sickling hemoglobins in sickle cell disease : application to gene therapy strategies

Hebert, N. (2020) · theses.fr (ABES) · doi:10.70675/7100e782ze144z4a6cz8bd0z88c8e98484f0

Répercussions de la drépanocytose en fonction du genre, d'un traitement médicamenteux et de l'entraînement en endurance sur le tissu musculaire, son phénotype et ses capacités métaboliques.

Riccetti, M. (2022) · theses.fr (ABES) · doi:10.70675/bb5621fcz3cbcz47edz8e65zee28aa379889

Effets combinés de stratégies thérapeutiques et d'un entraînement en endurance sur la fonction musculaire et le métabolisme énergétique chez le modèle murin Townes de la drépanocytose

Michel, C. P. (2022) · theses.fr (ABES) · doi:10.70675/a23402d9z6576z4a4ez84eczba2d94df994d

Étude phénotypique et fonctionnelle des progéniteurs myéloïdes dans la drépanocytose

Serra, M. (2023) · theses.fr (ABES) · doi:10.70675/b36dbc93zd0f3z4c37za604z5321671ab3e3

Short-RInChIKey=SA-FUHFF-UHFFFADPSC-GNZIZUAPFW-UHFFFADPSC-NUHFF-NUHFF-NUHFF-ZZZ

Freund, P., & Bach, T. (2026) · chemotion · doi:10.14272/reaction/sa-fuhff-uhfffadpsc-gnzizuapfw-uhfffadpsc-nuhff-nuhff-nuhff-zzz

Treatment of Ischemic Priapism: Challenges, Limitations, and Future Directions for Novel Treatment Regimens

Tiwary, P., Oswal, K., & Varghese, R. (2026) · Sexes · doi:10.3390/sexes7030036

High‐Throughput Experimentation‐Assisted Optimization of the Suzuki–Miyaura Coupling Using Palladium– N ‐Heterocyclic Carbene Precatalysts

Logvinov, A. A., Medina, F., Lefort, L., Rombouts, G., Jouffroy, M., & Nolan, S. P. (2026) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.70663

Schiff bases derived from 2-acetylcyclopentan-1-one with acetohydrazide and benzohydrazide: Synthesis, X-ray and DFT characterization, and in silico evaluation as potential hemoglobin S inhibitors for sickle cell disease

Panova, E. V., Tursunov, M. A., Otamurodova, S. T., Voronina, J. К., & Safin, D. A. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147669

Comparative virtual screening of African natural products against sickle haemoglobin: the β-chain hydrophobic acceptor pocket outperforms the Valβ6 surface for lateral-contact inhibition

BELLA, J. Y. T., & Zintchem, A. A. À. (2026) · Molecular Simulation · doi:10.1080/08927022.2026.2743768

A second-generation “hypoxia in a pill” rescues neurodegenerative phenotypes across distinct mouse models

Wang, H., Marutani, E., Zazzeron, L., Menard, M. A., Volpicelli‐Daley, L. A., Ichinose, F., & Mootha, V. K. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2618654123

BindingDB Entry 50021193: Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.

BindingDB (2025) · UC San Diego · doi:10.7270/q2vm4hvh

GBT 440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

Oksenberg, D., Dufu, K., Patel, M. P., Chuang, C.-Y., Li, Z., Xu, Q. R., Silva‐Garcia, A., Zhou, C., Hutchaleelaha, A., Patskovska, L. N., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14214 · Cited by 244

GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species

Hutchaleelaha, A., Patel, M. P., Silva, A., Oksenberg, D., & Metcalf, B. (2015) · Blood · doi:10.1182/blood.v126.23.2172.2172 · Cited by 10

Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia

Strader, M. B., Liang, H., Meng, F., Delenko, J., Ostrowski, D. A., Henry, E. R., Shet, A. S., Eaton, W. A., Thein, S. L., & Alayash, A. I. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00130 · Cited by 19

Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects

Rademacher, P. M., Hutchaleelaha, A., Washington, C. B., Lehrer, J., & Ramos, E. L. (2016) · Blood · doi:10.1182/blood.v128.22.2487.2487 · Cited by 11

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Lehrer‐Graiwer, J., Howard, J., Hemmaway, C. J., Awogbade, M., Telfer, P. T., Layton, M., Mant, T., Dufu, K., Hutchaleelaha, A., Koller, T. D., et al. (2015) · Blood · doi:10.1182/blood.v126.23.542.542 · Cited by 29